Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Predicting the future of anti-tumor necrosis factor therapy"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Predicting the future of anti-tumor necrosis factor therapy. | Available online http arthritis-research.eom content 11 3 115 Editorial Predicting the future of anti-tumor necrosis factor therapy Cornelis L Verweij Division of Inflammatory Disease Profiling Department of Pathology and Rheumatology VU University Medical Center P.O. Box 7057 1007MB Amsterdam The Netherlands Corresponding author Cornelis L Verweij c.verweij@vumc.nl Published 22 June 2009 Arthritis Research Therapy 2009 11 115 doi 10.1186 ar2724 This article is online at http arthritis-research.com content 11 3 115 2009 BioMed Central Ltd See related research by Hueber et al. http arthritis-research.com content 11 3 R76 Abstract Tumor necrosis factor TNF antagonists are approved worldwide for the treatment of rheumatoid arthritis RA . Clinical experience revealed that TNF-blocking therapy is effective for only approximately two thirds of patients reflecting that there are responders as well as nonresponders . Given the destructive nature of RA the risk of adverse effects and considerable costs for therapy there is a strong need to make predictions on success before the start of therapy. In the current issue of Arthritis Research Therapy Hueber and colleagues become the first to present a multiparameter serum protein biomarker set that has predictive value prior to the start of anti-TNF treatment. Ultimately this finding may contribute to a personalized form of medicine whereby a specific therapy will be applied that is best suited to an individual patient. The concept of a personalized form of medicine has attracted interest in the search for molecular and clinical criteria to dissect anti-tumor necrosis factor TNF responders from non-responders in rheumatoid arthritis RA . Essentially two phases of unresponsiveness might be identified a primary phase directly after the start of treatment and a secondary phase that develops in initial responders during the course of therapy. The latter is explained by the formation of anti-drug antibodies anti-anti-TNF antibodies .